Tactile Systems Technology (NASDAQ: TCMD), known in the market as Tactile Medical, has released its 2026 revenue projections, setting a target range of $360 million to $366 million. This financial forecast is notably contingent upon the normalization of airway clearance ordering, which the company anticipates will occur by the fourth quarter of 2026.
The outlook follows a period of strong operational performance. During the second quarter of 2026, Sheri Dodd, CEO, President & Director, commented on the company’s execution, stating, “We delivered another strong quarter of execution in Q2, highlighted by continued strength in our lymphedema business and meaningful profitability expansion.” This indicates a robust foundation and positive momentum heading into the forecast period, driven by key product segments.
The specific revenue range for 2026 underscores Tactile Medical’s strategic focus and market expectations. The sustained strength in its lymphedema business has been a consistent driver, contributing significantly to the company’s financial health. The projected normalization in airway clearance ordering is a critical variable, suggesting a return to more typical demand patterns for these products and playing a pivotal role in achieving the higher end of the revenue target.
Achieving these ambitious 2026 financial goals will require continued operational discipline and favorable market conditions, particularly as the company monitors the recovery and stability of its airway clearance product segment through the upcoming quarters.
